

THE CLAIMS DEFINING THE INVENTION ARE:

1. A composition for administration to animals including a combination of:

(a) at least one anti-arthritic agent selected from the group comprising

- i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
- ii) shark cartilage; with
- (b) at least one enhancing agent selected from the group of:

 a bark product or extract exhibiting antioxidant properties, and chrondratin compounds, and deer velvet, and vitamin E

and wherein the agent enhances the effect of the anti-arthritic agent.

- 2. A composition for administration to animals including a combination of :
 - (a) at least one anti-arthritic agent selected from the group comprising
 - i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
 - ii) shark cartilage; with
 - (b) at least one enhancing agent selected from the group of:


a bark product or plant product or extract exhibiting antioxidant properties,

chrondroitin compounds, and deer velvet, and vitamin E

and wherein the agent enhances the effect of the anti-arthritic agent.

- 3. A composition as claimed in either claim 1 or claim 2 which includes either or both of a green-lipped mussel extract (GLME) and a pharmaceutically active green lipped mussel product, in combination with any one or more of:

 shark cartilage, pharmacologically active shark extract, and chondroitin sulphate.
- 4. A composition as claimed in either claim 1 or claim 2 which includes an antiinflammatory agent in combination with a chondroitin compound.





Sub (

- A composition as claimed in either claim 1 or claim 2 which includes as the antiinflammatory agent either or both of shark cartilage and pharmacologically active
 shark cartilage extract in combination with any one or more of:
 - -EnzogenolTM, -PycnogenolTM, a bark extract equivalent to EnzogenolTM or PycnogenolTM, chondroitin sulphate, and a chondroitin compound.
- 6. A composition as claimed in any one of the preceding claims which includes, as an enhancing agent, PycnogenolTM.
- 7. A composition as claimed in any one of the preceding claims which includes one or more anti-oxidants other than Enzogenol or equivalent bark extracts.
- 8. A composition as claimed in claim 7 in which an anti-oxidant is vitamin E.
- 9. A composition as claimed in any one of the preceding claims which includes deer velvet or a pharmacologically active extract thereof.
- 10. A composition as claimed in any one of the preceding claims which includes additional glycosaminoglycans than those present in the selected anti-inflammatory or enhancing agents.
- 11. A composition as claimed in any one of the preceding claims which green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product in sufficient amount to provide gastro-intestinal protection against irritation by other components in the composition.
- 12. A composition as claimed in any one of the preceding claims which also includes any one or more of the following components:

 a vitamin, glycine, lysine, methionine, glutamic acid, tyrosine, and compounds providing in a pharmacologically acceptable form one or more of the following elements: manganese, zinc, iron, magnesium, selenium, calcium, copper, potassium, cobalt.
- 13. A composition as claimed in any one of the preceding claims which includes one or more pharmacologically active substances.

Sub /

- 14. A composition as claimed in claim 13 in which a pharmacologically active substance is an anti-inflammatory other than those listed in claim 1.
- 15. A composition as claimed in any one of the preceding claims formulated to be suitable for addressing any one or more of the following conditions in animals: inflammation, arthritis, chronic joint pain.
- 16. A composition as claimed in any one of the preceding claims in any one or more of the following forms:

as a bolus or tablet, in a capsule, as a slow release implant, as a liquid composition, as a gel, and as a paste.

- 17. A composition as claimed in any one of the preceding claims formulated for use with non-human mammals.
- 18. A method for addressing joint problems in non-human animals consisting of the administration of a composition as claimed in any one of the preceding claims.
- 19. A method as claimed in claim 18 in which the method of administration is oral.
- 20. A composition substantially as described herein with reference to the contained examples.
- 21. A method for addressing joint problems, substantially as described herein with reference to the contained examples.

22. The use of any two or more of:

- i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product,
- ii) shark cartilage and/or pharmacologically active shark cartilage extract;
- iii) an antioxidant bark extract,

in the preparation of a composition for use in addressing any one or more of:

- a) inflammation;
- b) degenerative joint complaints;
- c) other cartiligenous degeneration;
- d) gastrointestinal sensitivity or irritation;
- e) cancerous tumours;

